01 — Executive Summary
The drug discovery problem is fundamentally a computational problem that AI and quantum computing are uniquely positioned to solve.
The pharmaceutical industry has operated under a productivity paradox for four decades. Research and development spending has increased dramatically in real terms while the number of new molecular entities approved per billion dollars of research investment has declined. The cost of bringing a single new drug to market now exceeds two billion dollars by most estimates, with failure rates at late clinical stages that consume the majority of that investment without producing an approved therapy.
Two emerging approaches, applied together with appropriate organizational architecture, have the potential to produce structural improvement: artificial intelligence applied to the early stages of drug discovery and development, and quantum computing applied to the molecular simulation bottleneck that sits at the center of the productivity problem. This paper examines both in depth, with specific attention to the organizational and architectural decisions that determine whether life sciences organizations capture genuine advantage or pursue expensive demonstrations that do not reach the clinic.
The organizations that will lead pharmaceutical innovation in 2030 are not the ones with the largest research and development budgets. They are the ones that have redesigned the discovery workflow around the computational capabilities available today and that compound in value as production data accumulates.
02 — Sector Context
Why pharmaceutical productivity has declined despite massive investment, and what AI and quantum computing change about the underlying economics.
The pharmaceutical productivity decline is not primarily explained by the increasing difficulty of finding novel therapeutic targets, though that difficulty is real. It is primarily explained by the structural inefficiency of the discovery and development process at the molecular level. The process of identifying a molecule with the right combination of efficacy, selectivity, pharmacokinetic properties, and safety profile to survive clinical development involves searching a chemical space of extraordinary size with tools that were not designed for that search problem.
Drug-like chemical space is estimated to contain between ten to the power of twenty-three and ten to the power of sixty discrete molecules. The entire history of pharmaceutical research has explored a vanishingly small fraction of this space. The tools used to explore it, high-throughput screening, structure-activity relationship analysis, and computational docking, are each limited in ways that cause the search to converge on regions of chemical space that have already been explored, producing the diminishing returns dynamic that characterizes the productivity paradox.
AI changes the search problem in a specific and important way: generative AI models trained on existing molecular data can propose candidate molecules in unexplored regions of chemical space that satisfy specified property constraints. Quantum computing changes a different and more fundamental bottleneck: the accuracy of molecular simulation. The reason computational docking and structure-activity relationship models produce imprecise predictions is that the underlying physics of molecular interaction is quantum mechanical in nature and cannot be simulated exactly by classical computers for molecules of drug-relevant complexity.
4.2×
improvement in early-stage hit rate reported by organizations using AI-driven generative molecular design versus high-throughput screening alone, per Nature Biotechnology research
03 — Drug Discovery
How AI is restructuring target identification, lead generation, and candidate optimization.
Target identification and validation
The identification of a biological target whose modulation will produce a desired therapeutic effect without unacceptable off-target consequences is the foundational step in the drug discovery process and one of the most common sources of late-stage failure. Drugs that fail in Phase II and Phase III clinical trials most frequently fail because the target hypothesis was incorrect, the patient population in which the target is relevant was not correctly identified, or both.
AI systems trained on genomic, proteomic, and clinical data can identify target hypotheses that human researchers would not generate through hypothesis-driven research, because they identify patterns in multi-modal data at scales and dimensionalities that exceed human analytical capacity. More importantly, they can identify the patient subpopulations in which a given target hypothesis is most likely to hold, which transforms the clinical development strategy from population-level hypothesis testing to precision medicine investigation in a defined patient population.
Generative molecular design
Generative AI models for molecular design represent a qualitative shift in the lead generation process. Rather than screening a library of existing compounds against a target and identifying the best performers, generative models propose novel molecular structures predicted to satisfy specified property constraints: binding affinity to the target, selectivity against off-target proteins, oral bioavailability, metabolic stability, toxicity prediction, and synthetic accessibility.
The practical consequence is that the lead generation process begins not with the best molecule that exists in a screening library, but with a molecule designed specifically for the therapeutic problem at hand. The starting point for medicinal chemistry optimization is qualitatively better, which compresses the optimization timeline and reduces the probability of hitting fundamental property trade-offs that cannot be resolved without abandoning the chemical series.
ADMET prediction and candidate optimization
Absorption, distribution, metabolism, excretion, and toxicity properties are the most common causes of late-stage clinical failure for molecules that showed adequate efficacy in preclinical studies. AI models trained on larger and more diverse datasets, combined with active learning approaches that use experimental data to improve predictions in real time, produce ADMET predictions that are more accurate for novel chemical series and that can be used to guide synthetic strategy toward candidates with improved property profiles before significant synthesis investment is made.
04 — Clinical Development
How AI is changing trial design, patient stratification, and the use of real-world evidence.
Adaptive trial design and operational efficiency
Adaptive trial designs modify the protocol during execution in response to accumulating data, using pre-specified decision rules: dropping underperforming arms, adjusting dosing, re-stratifying the patient population, or stopping early for efficacy or futility. AI systems that process accumulating trial data in real time and generate recommendations for adaptive decisions can identify the optimal adaptation point earlier than human review processes, reducing both the time and the patient exposure required to reach a definitive conclusion.
Patient stratification and precision enrollment
Trial failure is frequently a population heterogeneity problem: a therapy that is effective in a defined patient subpopulation fails in a trial that enrolled an undifferentiated population because the signal from the responding subpopulation is diluted by the noise from the non-responding subpopulation. AI systems trained on genomic, biomarker, and clinical data can identify the molecular characteristics that predict treatment response, enabling trial enrollment strategies that concentrate the responding population and produce positive outcomes with smaller sample sizes in shorter timeframes.
60%
of Phase III clinical failures are attributable to inadequate patient stratification or incorrect target population definition, per BIO, Biomedtracker, and Amplion research
05 — Quantum Simulation
Why quantum computing solves the molecular simulation bottleneck at the center of pharmaceutical productivity.
The molecular simulation bottleneck is the most fundamental computational constraint in pharmaceutical research. Every property that determines whether a drug candidate will succeed in the clinic depends on quantum mechanical interactions at the molecular level that classical computers cannot simulate exactly for molecules of drug-relevant complexity.
Classical molecular simulation methods make approximations that allow tractable computation at the cost of accuracy. Density functional theory approximates the exchange-correlation energy of electron-electron interactions in ways that produce systematic errors for certain classes of molecular interactions that are particularly relevant to pharmaceutical binding problems. These errors are systematic, not random, which means that computational screening is biased toward the types of molecular interactions that classical methods handle well and away from the types that would require better approximations.
Quantum computers represent quantum mechanical systems natively. They do not need to approximate quantum mechanical behavior because they operate according to the same quantum mechanical principles. In Joemah's documented engagements with pharmaceutical simulation workflows, hybrid quantum-classical approaches have produced speedups of between fifteen and twenty-five times compared to purely classical methods for targeted molecular simulation tasks within drug discovery programs.
20×
documented speedup in targeted molecular simulation using hybrid quantum-classical workflows versus purely classical approaches in Joemah pharmaceutical engagements
06 — Regulatory Governance
How the FDA AI framework and ICH E9(R1) create specific architecture requirements for AI systems in drug development.
The regulatory framework governing AI in pharmaceutical development is evolving rapidly, with the FDA having published multiple guidance documents on AI and machine learning in drug development and medical devices that establish expectations for the governance of AI systems used in regulatory submissions. These expectations have specific architectural implications that organizations must design for before deploying AI in development workflows that will generate data used in regulatory filings.
The FDA's framework for AI and machine learning-based software as a medical device establishes a predetermined change control plan requirement: AI systems that learn from post-deployment data must have a specified plan for how the system will change, what changes require new regulatory submission, and how the performance of the changed system will be validated. This requirement implies a logging and monitoring infrastructure that tracks model performance over time, captures the data used for post-deployment learning, and provides the audit trail required to demonstrate that changes stayed within the predetermined change control plan.
ICH E9(R1), the international guideline on estimands and sensitivity analysis in clinical trials, has implications for AI systems used in trial data analysis. Organizations using AI to generate analyses for regulatory submissions must design their AI systems to produce outputs that satisfy the estimand specification requirements of the protocol, which constrains the system's output architecture in ways that must be known before the system is designed.
07 — Joemah Approach
How Joemah structures life sciences AI and quantum engagements from discovery through regulatory submission.
Joemah's life sciences practice structures engagements around three phases of the drug development process: discovery intelligence, clinical development optimization, and regulatory AI governance. These phases are connected by the cognitive architecture that the engagement designs to accumulate institutional knowledge across the full development lifecycle.
Discovery intelligence architecture
The discovery intelligence engagement designs the AI infrastructure that connects target identification, generative molecular design, ADMET prediction, and quantum simulation into a unified discovery workflow. The architecture is designed so that experimental data from each stage feeds back into the models used in prior stages, creating a compounding learning system that improves its predictions with every experiment the organization runs. Organizations that build this architecture early accumulate a proprietary experimental dataset that cannot be replicated by competitors even if they purchase the same underlying models.
Clinical development optimization
The clinical development engagement designs the AI infrastructure for adaptive trial management, patient stratification, and real-world evidence integration. It is governed from the outset by the FDA and ICH requirements that will apply to the data the system generates, ensuring that every analytical output produced by the system satisfies the regulatory expectations that will govern its use in a submission.
Regulatory AI governance
The regulatory governance engagement produces the predetermined change control plan, the performance monitoring infrastructure, and the audit trail architecture required for AI systems used in regulatory submissions. It is designed to satisfy current FDA expectations and to be adaptable to the evolving regulatory framework without requiring system rearchitecture.
08 — Conclusion
The organizations that redesign their discovery workflows around today's AI and quantum capabilities will compound that advantage across every development cycle that follows.
The pharmaceutical productivity paradox is not intractable. It is the product of a search process that has not been redesigned to take advantage of the computational tools now available. AI-driven generative molecular design, quantum simulation of molecular interactions, adaptive clinical trial management, and precision patient stratification collectively address the specific bottlenecks that have driven the productivity decline.
The organizations that redesign their discovery and development workflows around these capabilities will not simply improve their current programs. They will accumulate a proprietary experimental intelligence base that makes every subsequent program faster, cheaper, and more likely to succeed. Joemah works with life sciences organizations that are ready to make this architectural investment with precision and with the regulatory governance required to use AI-generated data in submissions.
01 — Executive Summary
The drug discovery problem is fundamentally a computational problem that AI and quantum computing are uniquely positioned to solve.
The pharmaceutical industry has operated under a productivity paradox for four decades. Research and development spending has increased dramatically in real terms while the number of new molecular entities approved per billion dollars of research investment has declined. The cost of bringing a single new drug to market now exceeds two billion dollars by most estimates, with failure rates at late clinical stages that consume the majority of that investment without producing an approved therapy.
Two emerging approaches, applied together with appropriate organizational architecture, have the potential to produce structural improvement: artificial intelligence applied to the early stages of drug discovery and development, and quantum computing applied to the molecular simulation bottleneck that sits at the center of the productivity problem. This paper examines both in depth, with specific attention to the organizational and architectural decisions that determine whether life sciences organizations capture genuine advantage or pursue expensive demonstrations that do not reach the clinic.
The organizations that will lead pharmaceutical innovation in 2030 are not the ones with the largest research and development budgets. They are the ones that have redesigned the discovery workflow around the computational capabilities available today and that compound in value as production data accumulates.
02 — Sector Context
Why pharmaceutical productivity has declined despite massive investment, and what AI and quantum computing change about the underlying economics.
The pharmaceutical productivity decline is not primarily explained by the increasing difficulty of finding novel therapeutic targets, though that difficulty is real. It is primarily explained by the structural inefficiency of the discovery and development process at the molecular level. The process of identifying a molecule with the right combination of efficacy, selectivity, pharmacokinetic properties, and safety profile to survive clinical development involves searching a chemical space of extraordinary size with tools that were not designed for that search problem.
Drug-like chemical space is estimated to contain between ten to the power of twenty-three and ten to the power of sixty discrete molecules. The entire history of pharmaceutical research has explored a vanishingly small fraction of this space. The tools used to explore it, high-throughput screening, structure-activity relationship analysis, and computational docking, are each limited in ways that cause the search to converge on regions of chemical space that have already been explored, producing the diminishing returns dynamic that characterizes the productivity paradox.
AI changes the search problem in a specific and important way: generative AI models trained on existing molecular data can propose candidate molecules in unexplored regions of chemical space that satisfy specified property constraints. Quantum computing changes a different and more fundamental bottleneck: the accuracy of molecular simulation. The reason computational docking and structure-activity relationship models produce imprecise predictions is that the underlying physics of molecular interaction is quantum mechanical in nature and cannot be simulated exactly by classical computers for molecules of drug-relevant complexity.
4.2×
improvement in early-stage hit rate reported by organizations using AI-driven generative molecular design versus high-throughput screening alone, per Nature Biotechnology research
03 — Drug Discovery
How AI is restructuring target identification, lead generation, and candidate optimization.
Target identification and validation
The identification of a biological target whose modulation will produce a desired therapeutic effect without unacceptable off-target consequences is the foundational step in the drug discovery process and one of the most common sources of late-stage failure. Drugs that fail in Phase II and Phase III clinical trials most frequently fail because the target hypothesis was incorrect, the patient population in which the target is relevant was not correctly identified, or both.
AI systems trained on genomic, proteomic, and clinical data can identify target hypotheses that human researchers would not generate through hypothesis-driven research, because they identify patterns in multi-modal data at scales and dimensionalities that exceed human analytical capacity. More importantly, they can identify the patient subpopulations in which a given target hypothesis is most likely to hold, which transforms the clinical development strategy from population-level hypothesis testing to precision medicine investigation in a defined patient population.
Generative molecular design
Generative AI models for molecular design represent a qualitative shift in the lead generation process. Rather than screening a library of existing compounds against a target and identifying the best performers, generative models propose novel molecular structures predicted to satisfy specified property constraints: binding affinity to the target, selectivity against off-target proteins, oral bioavailability, metabolic stability, toxicity prediction, and synthetic accessibility.
The practical consequence is that the lead generation process begins not with the best molecule that exists in a screening library, but with a molecule designed specifically for the therapeutic problem at hand. The starting point for medicinal chemistry optimization is qualitatively better, which compresses the optimization timeline and reduces the probability of hitting fundamental property trade-offs that cannot be resolved without abandoning the chemical series.
ADMET prediction and candidate optimization
Absorption, distribution, metabolism, excretion, and toxicity properties are the most common causes of late-stage clinical failure for molecules that showed adequate efficacy in preclinical studies. AI models trained on larger and more diverse datasets, combined with active learning approaches that use experimental data to improve predictions in real time, produce ADMET predictions that are more accurate for novel chemical series and that can be used to guide synthetic strategy toward candidates with improved property profiles before significant synthesis investment is made.
04 — Clinical Development
How AI is changing trial design, patient stratification, and the use of real-world evidence.
Adaptive trial design and operational efficiency
Adaptive trial designs modify the protocol during execution in response to accumulating data, using pre-specified decision rules: dropping underperforming arms, adjusting dosing, re-stratifying the patient population, or stopping early for efficacy or futility. AI systems that process accumulating trial data in real time and generate recommendations for adaptive decisions can identify the optimal adaptation point earlier than human review processes, reducing both the time and the patient exposure required to reach a definitive conclusion.
Patient stratification and precision enrollment
Trial failure is frequently a population heterogeneity problem: a therapy that is effective in a defined patient subpopulation fails in a trial that enrolled an undifferentiated population because the signal from the responding subpopulation is diluted by the noise from the non-responding subpopulation. AI systems trained on genomic, biomarker, and clinical data can identify the molecular characteristics that predict treatment response, enabling trial enrollment strategies that concentrate the responding population and produce positive outcomes with smaller sample sizes in shorter timeframes.
60%
of Phase III clinical failures are attributable to inadequate patient stratification or incorrect target population definition, per BIO, Biomedtracker, and Amplion research
05 — Quantum Simulation
Why quantum computing solves the molecular simulation bottleneck at the center of pharmaceutical productivity.
The molecular simulation bottleneck is the most fundamental computational constraint in pharmaceutical research. Every property that determines whether a drug candidate will succeed in the clinic depends on quantum mechanical interactions at the molecular level that classical computers cannot simulate exactly for molecules of drug-relevant complexity.
Classical molecular simulation methods make approximations that allow tractable computation at the cost of accuracy. Density functional theory approximates the exchange-correlation energy of electron-electron interactions in ways that produce systematic errors for certain classes of molecular interactions that are particularly relevant to pharmaceutical binding problems. These errors are systematic, not random, which means that computational screening is biased toward the types of molecular interactions that classical methods handle well and away from the types that would require better approximations.
Quantum computers represent quantum mechanical systems natively. They do not need to approximate quantum mechanical behavior because they operate according to the same quantum mechanical principles. In Joemah's documented engagements with pharmaceutical simulation workflows, hybrid quantum-classical approaches have produced speedups of between fifteen and twenty-five times compared to purely classical methods for targeted molecular simulation tasks within drug discovery programs.
20×
documented speedup in targeted molecular simulation using hybrid quantum-classical workflows versus purely classical approaches in Joemah pharmaceutical engagements
06 — Regulatory Governance
How the FDA AI framework and ICH E9(R1) create specific architecture requirements for AI systems in drug development.
The regulatory framework governing AI in pharmaceutical development is evolving rapidly, with the FDA having published multiple guidance documents on AI and machine learning in drug development and medical devices that establish expectations for the governance of AI systems used in regulatory submissions. These expectations have specific architectural implications that organizations must design for before deploying AI in development workflows that will generate data used in regulatory filings.
The FDA's framework for AI and machine learning-based software as a medical device establishes a predetermined change control plan requirement: AI systems that learn from post-deployment data must have a specified plan for how the system will change, what changes require new regulatory submission, and how the performance of the changed system will be validated. This requirement implies a logging and monitoring infrastructure that tracks model performance over time, captures the data used for post-deployment learning, and provides the audit trail required to demonstrate that changes stayed within the predetermined change control plan.
ICH E9(R1), the international guideline on estimands and sensitivity analysis in clinical trials, has implications for AI systems used in trial data analysis. Organizations using AI to generate analyses for regulatory submissions must design their AI systems to produce outputs that satisfy the estimand specification requirements of the protocol, which constrains the system's output architecture in ways that must be known before the system is designed.
07 — Joemah Approach
How Joemah structures life sciences AI and quantum engagements from discovery through regulatory submission.
Joemah's life sciences practice structures engagements around three phases of the drug development process: discovery intelligence, clinical development optimization, and regulatory AI governance. These phases are connected by the cognitive architecture that the engagement designs to accumulate institutional knowledge across the full development lifecycle.
Discovery intelligence architecture
The discovery intelligence engagement designs the AI infrastructure that connects target identification, generative molecular design, ADMET prediction, and quantum simulation into a unified discovery workflow. The architecture is designed so that experimental data from each stage feeds back into the models used in prior stages, creating a compounding learning system that improves its predictions with every experiment the organization runs. Organizations that build this architecture early accumulate a proprietary experimental dataset that cannot be replicated by competitors even if they purchase the same underlying models.
Clinical development optimization
The clinical development engagement designs the AI infrastructure for adaptive trial management, patient stratification, and real-world evidence integration. It is governed from the outset by the FDA and ICH requirements that will apply to the data the system generates, ensuring that every analytical output produced by the system satisfies the regulatory expectations that will govern its use in a submission.
Regulatory AI governance
The regulatory governance engagement produces the predetermined change control plan, the performance monitoring infrastructure, and the audit trail architecture required for AI systems used in regulatory submissions. It is designed to satisfy current FDA expectations and to be adaptable to the evolving regulatory framework without requiring system rearchitecture.
08 — Conclusion
The organizations that redesign their discovery workflows around today's AI and quantum capabilities will compound that advantage across every development cycle that follows.
The pharmaceutical productivity paradox is not intractable. It is the product of a search process that has not been redesigned to take advantage of the computational tools now available. AI-driven generative molecular design, quantum simulation of molecular interactions, adaptive clinical trial management, and precision patient stratification collectively address the specific bottlenecks that have driven the productivity decline.
The organizations that redesign their discovery and development workflows around these capabilities will not simply improve their current programs. They will accumulate a proprietary experimental intelligence base that makes every subsequent program faster, cheaper, and more likely to succeed. Joemah works with life sciences organizations that are ready to make this architectural investment with precision and with the regulatory governance required to use AI-generated data in submissions.
Apply this to your organization
© 2025 Joemah. All rights reserved.
joemah.com/whitepaper/life-sciences